I am a
Home I AM A Search Login

Papers of the Week


2022 Jan 20


J Allergy Clin Immunol

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results.

Authors

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis G M, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM
J Allergy Clin Immunol. 2022 Jan 20.
PMID: 35086692.

Abstract

Attacks of hereditary angioedema are attributed to excessive plasma kallikrein (PKa) activity, which cleaves high-molecular-weight kininogen to generate the proinflammatory hormone bradykinin.